Wonder when the ATH434 effect on FA IPSC model results will be released.
Biogen bought Reata Pharma in 2023 for $7.3bn USD to acquire just one drug Skyclarys (omaveloxolene) which slows FA progression by 55% and which had been FDA approved after a phase 2 trial. So shows the potential in FA space for ATH434 if it can help those patients, especially if just one phase 2 registrational trial is needed like it was for Skyclarys.
I'm hoping this FA IPSC model data is quite good, putting us in a stronger negotiating position if any partnering/buying talks happen early next year after 201 results. I feel they are building the FA case nicely to release some good results soon, time will tell I guess.
Cheers, all IMOhttps://www.fiercepharma.com/pharma/how-biogen-outbid-rival-pharma-claim-reata-its-own-73b
https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(23)00281-2
Ann: Alterity Presents Data Describing Neuroprotection of ATH434, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.1¢ | $88.06K | 8.054M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 11330464 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 1574126 | 5 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |